Early Palliative Care in Metastatic Lung Cancer in Northern France

Impact of Early Palliative Care on Quality of Life and Survival of Patients With Non-small-cell Metastatic Lung Cancer in Northern France

Single-center, prospective, controlled, open-label, randomized, two parallel arms comparing early Palliative care versus Standard care in patients with non-small-cell metastatic lung cancer

144 patients will be included; 72 per arm.

• "Standard" Control arm: patient supported by the onco-respiratory service.
• Intervention arm: patients benefit from early palliative care in addition to standard onco-pneumologic care.

The main criterion of judgment is the TOI score measured at 12 weeks.

FACTL questionnaires, HADS and PHQ-9 will be filled out before randomization , at 12 weeks and 21 weeks

Inclusion Criteria:

• Being diagnosed with non-small cell lung cancer

  • Proven histologically
  • Metastatic proven imaging (MRI, CT Scanner, PET scan)
  • Stage IV (any T, any N, M1)

• prior to secondary chemotherapy treatment.

• Age> 18 years

• PS ≤2

• Patient able to understand the nature, purpose and methodology of the study

• signed Informed consent

Exclusion Criteria:

• Age <18 years
• Patient already supported by palliative care
• Patient with an activating EGFR mutation or EML4-ALK rearrangement or ROS1 gene translocation
• Patient under trusteeship / guardianship